MAP2K7 and melanoma: In a phase Ib/II, open-label clinical trial, 102 patients with locally advanced or metastatic NRAS-mutant melanoma were treated with a MEK inhibitor (binimetinib), and a CDK4/6 inhibitor (ribociclib).